

Opdivo® (nivolumab) - Expanded indications

- On February 15, 2023, the <u>FDA approved</u> Bristol Myers Squibb <u>Opdivo (nivolumab)</u>, as a single agent or in combination with <u>Yervoy[®] (ipilimumab)</u>, for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic melanoma.
 - Opdivo was previously approved for this indication in adults only.
- In addition, the <u>FDA approved</u> Opdivo for the adjuvant treatment of adult and pediatric patients 12 years and older with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.
 - Opdivo was also previously approved for this indication in adults only.
- In addition to melanoma, Opdivo is approved for neoadjuvant treatment of resectable non-small cell lung cancer (NSCLC); metastatic NSCLC; malignant pleural mesothelioma; advanced renal cell carcinoma; classical Hodgkin lymphoma; squamous cell carcinoma of the head and neck; urothelial carcinoma; microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer; hepatocellular carcinoma; esophageal cancer; and gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.
- Refer to the Opdivo drug label for dosing and administration recommendations for all of its uses and indications.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.